Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB, a global biopharmaceutical company, has selected PAREXEL as one of its strategic partners for clinical development services across the globe.
Subscribe to our email newsletter
Under the agreement, both the companies will boost the clinical development besides increasing productivity and cost effectiveness.
UCB will receive the benefits of PAREXEL’s clinical processes through all phases of development, which are supported by its eClinical technology platform.
In addition, UCB will also support PAREXEL’s consulting expertise in regulatory affairs and commercialization.
UCB executive vice president and chief medical officer Iris Loew-Friedrich said PAREXEL would help UCB enhance efficiency and cost effectiveness, besides bringing improvement in delivery of new medicines to patients across the globe.
"PAREXEL will be instrumental in helping UCB expand our global drug development activities including in Asia," Loew-Friedrich added.